Pharmacogenetics of advanced lung cancer: Predictive value of functional genetic polymorphism AGXT Pro11Leu in clinical outcome?

• Main Author: Catarata, Maria Joana
• Publication Date: 2021
• Other Authors: Lourenço, Margarida, Martins, Maria Fátima, Frade, João, Pêgo, Alice, Cordeiro, Carlos Robalo, Medeiros, Rui, Ribeiro, Ricardo
• Format: Article
• Language: eng
• Source: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Download full: http://hdl.handle.net/10316/100782; https://doi.org/10.1016/j.pulmoe.2020.11.007
• topic: Non-small cell lung cancer; Single nucleotide polymorphism; Pharmacogenetics; Cohort study; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Progression-Free Survival; Retrospective Studies; Severity of Illness Index; Transaminases

Introduction AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents. The association of genetic variant AGXT rs34116584 on the clinical outcome and response to chemotherapy of patients with non-small cell lung cancer (NSCLC) remains to be established. Our aim was to evaluate the association of functional AGXT gene polymorphism in NSCLC progression, considering as primary and secondary endpoint, progression free survival (PFS) and overall survival (OS), respectively. Methods Genotyping of theAGXT rs34116584 genetic polymorphism was performed by mass spectrometry on 168 DNA samples from patients with NSCLC (stages IIIA-IVB). Univariate survival analysis included the study of Kaplan-Meier curves with the Log-Rank test, while Cox regression was used as a multivariate analysis. Results Multivariate analysis showed shorter PFS for T carriers [HR = 2.0, 95% CI, 1.4−3.0, p < 0.0001] and shorter OS [HR = 1.8, 95% CI, 1.1−3.0, p = 0.017] globally, as well as in a subgroup of patients (n = 144) treated with first line platinum-based chemotherapy [HR = 2.0, 95% CI, 1.3–3.1, p = 0.001] and [HR = 1.8, 95% CI, 1.1–3.1, p = 0.026], respectively. Conclusion This polymorphism seems to have an impact on NSCLC progression, opening new perspectives for its inclusion as a pharmacogenetic predictor of response to platinum-based chemotherapy.